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Background
It has become popular to be vaccinated against pneumonia
in Japan. It is reported that 23-valent pneumococcal poly-
saccharide vaccine prevents pneumonia and improves sur-
vival in nursing home residents in Japan [1]. However the
effect on medical expenses of that vaccine in a local area
has not yet been reported. We tried to evaluate it.
Materials and methods
In a prefecture, which is located in western part of
Japan, people over 75 years old have been assisted with
being vaccinated by an association responsible for
operation of the healthcare system for the elderly aged
75 and older since 2009. We tried to evaluate its effects
on medical expenses.
Results
Period A: From April 2009 till March 2012
Period B: From April 2012 till September 2012
The medical expenses for pneumonia of the vacci-
nated group (n=13689) and the non-vaccinated
(n=126110) group are compared using the medical prac-
titioners’ receipt for health insurance claim.
The medical examination rates in Period A were 0.403
per year in the vaccinated and 0.227 per year in the
non-vaccinated. Those in period B were 0.549 in the
vaccinated and 0.331 in the non-vaccinated. The
increasing rate of the vaccinated seems to be suppressed
compared to non-vaccinated.
Medical expenses in Period A were £365.2 in the vac-
cinated and £293.9 in the non-vaccinated. Those in Per-
iod B were £371.9 in the vaccinated and £172.1 in the
non-vaccinated. The increase in medical expense seems
to be suppressed by the vaccination.
Conclusion
The rate of the vaccinated in this prefecture is small.
And the Period B is too short. Also it seems that those
that are vaccinated have some diseases or are compro-
mised. However the vaccination seems to be effective in
reducing medical examination rate of pneumonia and
reducing the medical expenses for it.
These data have some limitations. Pneumonia on the
medical practitioners’ receipt is not only caused by
pneumococcus but also other causes such as virus. As
the bills of medical treatment are issued every month,
rates of diseases are sometimes overestimated. And the
medical expenses for the inpatient was not calculated as
they were not admitted only for pneumonia.
Effect of 23-valent pneumococcal polysaccharide vac-
cine seems to reduce pneumonia and medical expenses
even in a local area.
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